REG - FTSE Russell Mediclinic Intnl plc - Mediclinic International

Mediclinic InternationalAnnouncement

18/05/2023 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230518:nRSR9264Za&default-theme=true

RNS Number : 9264Z  FTSE Russell  18 May 2023

 

Mediclinic International (UK): Constituent Deletion

Changes in FTSE UK Index Series

18 May 2023

 Subject to court sanctioning the scheme of arrangement in relation to the cash
 offer for Mediclinic International (UK, constituent) by Manta Bidco Ltd (non
 constituent), please see details of affected indexes and effective dates
 below:

 

 Index                                   Effective From

Start of Trading
 FTSE 250 Index                          25 May 2023
 FTSE 350 Index                          25 May 2023
 FTSE All-Share Index                    25 May 2023
 FTSE All-Share ex Multinationals Index  25 May 2023
 FTSE 350 Lower Yield Index              25 May 2023

 

 Please note: FTSE Russell will issue a further notice detailing the
 replacement for Mediclinic International within the FTSE 250 Index, and the
 associated index changes, on Monday 22 May, based on the shares in issue and
 close prices as of Friday 19 May 2023.

 

 

 

 

 For further information please contact FTSE Russell Client Services at
 info@ftserussell.com or call:

Australia  +1800 653 680
 Hong Kong  +852 2164 3333
 Japan      +81 3 6441 1430
 London     +44 (0) 20 7866 1810
 New York   +1866 551 0617

Alternatively please visit our website at www.ftserussell.com
 (http://www.ftserussell.com)

 Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
 © 2023 FTSE Russell

Alternatively please visit our website at www.ftserussell.com
(http://www.ftserussell.com)

 

Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
© 2023 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FTSBBGDUCUBDGXI